Document ID: FDA-2011-N-0002-0045
Agency: fda
Document Type: Notice
Title: Medical Imaging Drugs Advisory Committee; Reestablishment
Posted Date: 2011-05-04T04:00Z

[Federal Register Volume 76, Number 86 (Wednesday, May 4, 2011)]
[Notices]
[Pages 25357-25358]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-10813]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0002]

Advisory Committee; Medical Imaging Drugs Advisory Committee; 
Reestablishment

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the

[[Page 25358]]

reestablishment of the Medical Imaging Drugs Advisory Committee in the 
Division of Advisory Committee and Consultants Management, Center for 
Drug Evaluation and Research.

FOR FURTHER INFORMATION CONTACT: Minh Doan, Center for Drug Evaluation 
and Research, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 31, rm. 2424, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 
301-847-8533, MIDAC@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Under the Federal Advisory Committee Act of 
October 6, 1972 (Pub. L. 92-463 (5 U.S.C. app. 2)); section 904 of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 394), as amended by the 
Food and Drug Administration Revitalization Act (Pub. L. 101-635); and 
21 CFR 14.40(b), FDA is announcing the reestablishment of the Medical 
Imaging Drugs Advisory Committee by the Commissioner of Food and Drugs 
(the Commissioner). A notice announcing a request for nominations for 
members and representatives on the committee as well as a final rule 
adding the committee to the current list of committees in 21 CFR 14.100 
will be published at a later date.
    The Medical Imaging Drugs Advisory Committee reviews and evaluates 
data concerning the safety and effectiveness of marketed and 
investigational human drug products for use in diagnostic and 
therapeutic procedures using radioactive pharmaceuticals and contrast 
media used in diagnostic radiology and makes appropriate 
recommendations to the Commissioner.
    The Medical Imaging Drugs Advisory Committee shall consist of a 
core of 12 voting members including the chair. Members and the chair 
are selected by the Commissioner or designee from among authorities 
knowledgeable in the fields of nuclear medicine, radiology, 
epidemiology or statistics, and related specialties. Almost all non-
Federal members of this committee serve as special Government 
employees. The core of voting members may include one technically 
qualified member, selected by the Commissioner or designee, who is 
identified with consumer interests and is recommended by either a 
consortium of consumer-oriented organizations or other interested 
persons. In addition to the voting members, the committee may include 
one nonvoting member who is identified with industry interests.
    This notice is given under the Federal Advisory Committee Act and 
21 CFR part 14, relating to advisory committees.

    Dated: April 28, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-10813 Filed 5-3-11; 8:45 am]
BILLING CODE 4160-01-P